Comparative Analysis of miR-29a Expression in Optimized Medical Therapy and Intestinal Infusion Therapies in Advanced Parkinson’s Disease
Objective: To compare the relative expression of miR-29a in patients with advanced Parkinson's disease (PD) receiving optimized medical therapy (OMT) versus intestinal infusion therapies—levodopa/carbidopa intestinal…Sex specific role of dyslipidemia and statin use in Parkinson’s disease pathogenesis
Objective: Our aim was to characterize the role of dyslipidemia and statin use in Parkinson’s disease (PD) development, specifically with respect to differences in significance…The Impact of Statin Therapy on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Meta-Analysis
Objective: To assess the effects of statin therapy on motor and non-motor symptoms in Parkinson’s disease (PD) through a meta-analysis of randomized controlled trials. Background:…Bias in Pharmacoepidemiological Studies of Parkinson’s Disease Prescribing Patterns: A Systematic Review
Objective: This systematic review aims to identify and evaluate reported biases in pharmacoepidemiological studies on nonrandomized prescribing patterns, drug utilization, or treatment trends in PD.…The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs
Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…Unveiling the Molecular Mechanism of Polydatin in Ameliorating Parkinson’s Disease via the DRD2/CRYAB/NF-κB Axis in Astrocytes and Exploring Cell Therapy Strategies
Objective: Define polydatin's therapeutic mechanism targeting astrocyte-mediated neuroinflammation in Parkinson's disease (PD) and assess combinatorial efficacy with dopamine progenitor transplantation. Background: PD progression involves substantia…Relationship Between Improvement in “On” Time, Nonmotor Symptoms, and Quality of Life in Adults Treated With Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease
Objective: To determine if adults with advanced Parkinson’s disease (aPD) treated with a 24‑hour/day continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion who had ≥ 1‑hour improvement in…VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…Istradefylline for Freezing of Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To evaluate the effects of istradefylline on motor function and freezing of gait (FOG) in patients with Parkinson’s disease (PD). Background: FOG is a…Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion
Objective: To investigate the relationship between improvements in sleep disturbances and quality of life (QoL) in adults with advanced Parkinson’s disease (aPD) treated with a…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 36
- Next Page »